Public consultation on interim decisions to amend the Poisons Standard - November 2020 ACMS/ACCS meetings

Closed 4 Mar 2021

Opened 3 Feb 2021

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 19 Jul 2021

We asked

Public consultation on the Delegate’s interim decision, in relation to scheduling proposals referred to the November 2020 meetings of the Advisory Committee on Medicines and Chemicals Scheduling, was held between 3 February 2021 and 4 March 2021.

You said

We received 807 submissions in response to the public consultation, including one submission that was received offline. Respondents provided feedback on the proposed changes to the Poisons Standard. We appreciate all of the feedback that we received.

We did

The Delegate’s final decisions on psilocybin and MDMA were deferred on 7 April 2021, pending an independent expert review and additional committee advice. The Delegate will consider all evidence provided, including the public submissions received, ahead of making the final decisions on these substances.

The final decisions for all other substances considered at the November 2020 meetings were published on 22 April 2021 on the TGA website.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Scheduling amendments referred to expert advisory committee

This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 4-5 November 2020 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 4 March 2021. All submissions received by the deadline will be considered by the delegate before they make a final decision.

The interim decisions under consultation are detailed in the public notice of interim decisions of February 2021.

Substances for which public comment is sought

  • Item 2.1 - Amygdalin and hydrocyanic acid
  • Item 2.2 - Bilastine
  • Item 2.3 - Budesonide + formoterol
  • Item 2.4 - Psilocybin
  • Item 2.5 - N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine (MDMA)
  • Item 3.1 - Azoxystrobin
  • Item 3.2 - Triticonazole
  • Item 4.1 - Azelaic acid
  • Item 4.2 - 2-hydroxyethyl methacrylate
  • Item 4.3 - Magnesium hydroxide
  • Item 4.4 - Tetrahydrofurfuryl alcohol (THFA)
  • Item 4.5 - Cannabidiol (private application)

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Following consideration of public submissions received before the closing date and advice from the expert advisory committee/s, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions  in April 2021.

Audiences

  • General public

Interests

  • Legislation